目的: 探讨CD26及CLDN1在甲状腺乳头状癌(papillary thyroid carcinoma, PTC)防治中的临床应用价值。方法: 选择包头市肿瘤医院2021年12月-2022年12月收治的48例PTC患者病理组织切片标本,将肿瘤组织作为实验组,癌旁组织作为对照组。采用免疫组化法对两组组织中CD26、CLDN1表达水平进行测定,采用SPSS 27.0分析PTC患者组织中CD26、CLDN1与临床病理之间的关系,各组数据阳性率间的相关性采用Spearman相关分析检验(α＝0.05)。结果: 癌组织CD26、CLDN1阳性表达率分别为85.42%、83.33%,高于癌旁组的27.08%和20.83%,差异均有统计学意义(P＜0.05); 在不同PTC患者年龄、性别、最大肿瘤直径、单侧、双侧甲状腺腺叶上的肿瘤、有无侵犯包膜,CD26、CLDN1蛋白阳性表达率差异无统计学意义(均P＞0.05)。CD26、CLDN1与淋巴结转移均存在相关性(P＜0.05);CD26与CLDN1在PTC组织中表达有明显的正相关性(rs＝0.294,P＜0.05)。结论: CD26、CLDN1在PTC发生发展中扮演重要角色,联合检测这两种蛋白有助于PTC的诊断和治疗。
Objective: To investigate the clinical value of CD26 and CLDN1 in the prevention and treatment of papillary thyroid carcinoma (PTC). Methods: Pathological tissue section specimens of 48 surgical patients with PTC admitted to Baotou Cancer Hospital from December 2021 to December 2022 were selected, with tumor tissues as the experimental group and adjacent tissues as the control group. The expression levels of CD26 and CLDN1 in the two groups were measured by immunohistochemistry. SPSS 27.0 was used to analyze the relationship between CD26, CLDN1 and clinicopathology in PTC patients. The correlation between the positive rates of each group was tested by Spearman correlation analysis (α＝0.05). Results: The positive expression rates of CD26 and CLDN1 in tumor tissues were 85.42% and 83.33%, respectively, which were higher than 27.08% and 20.83% in adjacent tissues, and the differences were statistically significant (P＜0.05). There was no significant difference in the positive expression rate of CD26 and CLDN1 protein in different PTC patients with different age, gender, maximum tumor diameter, unilateral, bilateral thyroid gland tumors, and invasion of the capsule (all P＞0.05). CD26 and CLDN1 were correlated with lymph node metastasis(P＜0.05). There was a significant positive correlation between the expression of CD26 and CLDN1 in PTC tissues (rs＝0.294, P＜0.05). Conclusion: CD26 and CLDN1 play an important role in the occurrence and development of PTC. Combined detection of CD26 and CLDN1 is helpful to the diagnosis and treatment of PTC.
[1] Kim J, Gosnel JE, Roman SA. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16 (1): 17-29.
[2] Qiu Y, Fei Y, Liu J, et al. Prevalence, risk factors and location of skip metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis[J]. Cancer Manag Res, 2019, 25(11): 8721-8730.
[3] Chen Z, Yu J, Fu M, et al. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway[J]. Biochem Pharmacol, 2020, 177: 113951.
[4] Sobel G, Németh J, Kiss A, et al. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma[J]. Gynecol Oncol, 2006, 103(2): 591-598.
[5] Fritzsche FR, Oelrich B, Johannsen M, et al. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas[J]. Clin Cancer Res, 2008, 14: 7035-7042
[6] Resnick MB, Konkin T, Routhier J, et al.Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study[J]. Mod Pathol, 2005, 18: 511-518
[7] Borka K, Kaliszky P, Szabó E, et al. Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas[J]. Virchows Arch, 2007, 450(5): 549-557.
[8] Tokés AM, Kulka J, Paku S, et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study[J]. Breast Cancer Res, 2005, 7(2): R296-R305.
[9] Sobel G, Páska C, Szabó I,et al. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma[J]. Hum Pathol, 2005, 36(2): 162-169.
[10] Bhat AA, Syed N, Therachiyil L, et al. Claudin-1, a double-edged sword in cancer[J]. Int J Mol Sci, 2020, 21(2): 569.
[11] 仇以利, 陈一峰, 杨金玲, 等. RET/RAS/BRAF基因驱动甲状腺乳头状癌共表达关键基因的生物信息学分析[J]. 临床与实验病理学杂志, 2021, 37(6): 727-730.
[12] 陈志会, 杨艳, 凃玲, 等. 二肽基肽酶4及其抑制剂在新型冠状病毒肺炎防治中的研究进展[J]. 医药导报, 2021, 40(1): 90-93.
[13] Tanaka T, Umeki K, Yamamoto I, et al. CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma[J]. Int J Cancer, 1995, 64(5): 326-331.
[14] Tan X, Egami H, Ishikawa S, et al. Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells[J]. Int J Oncol, 2004, 25(6): 1567-1574.
[15] Furuse M, Furuse K, Sasaki H, et al. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells[J]. J Cell Biol, 2001, 153: 263-272.
[16] Resnick MB, Konkin T, Routhier J, et al. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study[J]. Mod Pathol, 2005, 18: 511-518.
